Prostate cancer awareness month may already be over, but men’s health remains an important topic. We are therefore most pleased to announce that ABX-CRO was chosen to collaborate with Curasight in a phase 2 study to improve the diagnosis of prostate cancer.

The primary objective of this phase 2 trial is to investigate Curasight’s first-in-class PET tracer, 64Cu-DOTA-AE105 as a non-invasive grading tool of prostate cancer patients that are followed in active surveillance.

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”).

Read more about the project in Curasight’s Press Release

Untitled Document